Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1988 Aug;94(4):1167–1174. doi: 10.1111/j.1476-5381.1988.tb11635.x

Alteration of fate of vasoactive autacoids in pulmonary circulation following monocrotaline-induced lung vascular injury in rats.

K Ito 1, K Hayashi 1, T Nakashima 1, T Murakami 1
PMCID: PMC1854105  PMID: 2463024

Abstract

1. To learn how pulmonary vascular injury alters the ability of the lung to metabolize vasoactive autacoids, lung vascular lesions were produced in rats by a single subcutaneous injection of monocrotaline (90 mg kg-1), and the blood pressure responses to angiotensin I (AI), angiotensin II (AII), bradykinin, prostaglandin E2 (PGE2) and substance P were examined. Vasoactive agents were given intravenously or intra-arterially. 2. On histological examination of the lung at 3 weeks after monocrotaline treatment, degeneration or necrotization of endothelial cells was evident. 3. The conversion of AI to AII was only slightly depressed by monocrotaline treatment. On the other hand, the depressor response to intravenously injected bradykinin was enhanced in monocrotaline-treated rats. When the rats were pretreated with indomethacin the depressor response to intravenous bradykinin was the same for both control and monocrotaline-treated groups which suggests that endogenous prostaglandins are involved in the enhancement of the response to bradykinin. 4. In monocrotaline-treated rats the depressor response to intravenous PGE2 was significantly enhanced depending on the period following the treatment, while that to the intra-arterial injection did not differ from control. 5. The data suggest that monocrotaline-induced lung injury impairs the metabolism of PGE2 during pulmonary circulation but has little effect on the conversion of AI to AII and the degradation of bradykinin in rats.

Full text

PDF
1167

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ali A. E., Barrett J. C., Eling T. E. Prostaglandin and thromboxane production by fibroblasts and vascular endothelial cells. Prostaglandins. 1980 Oct;20(4):667–688. doi: 10.1016/0090-6980(80)90107-0. [DOI] [PubMed] [Google Scholar]
  2. Altiere R. J., Olson J. W., Gillespie M. N. Altered pulmonary vascular smooth muscle responsiveness in monocrotaline-induced pulmonary hypertension. J Pharmacol Exp Ther. 1986 Feb;236(2):390–395. [PubMed] [Google Scholar]
  3. Anderson M. W., Eling T. E. Prostaglandin removal and metabolism by isolated perfused rat lung. Prostaglandins. 1976 Apr;11(4):645–677. doi: 10.1016/0090-6980(76)90067-8. [DOI] [PubMed] [Google Scholar]
  4. Armstrong J. M., Lattimer N., Moncada S., Vane J. R. Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin F1alpha with those of prostaglandin E2 in rats and rabbits. Br J Pharmacol. 1978 Jan;62(1):125–130. doi: 10.1111/j.1476-5381.1978.tb07014.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bakhle Y. S. Decreased inactivation of prostaglandin E2 in isolated lungs from rats with alpha-naphthyl thiourea-induced pulmonary oedema. Biochem Pharmacol. 1982 Nov 1;31(21):3395–3401. doi: 10.1016/0006-2952(82)90617-7. [DOI] [PubMed] [Google Scholar]
  6. Bakhle Y. S., Vane J. R. Pharmacokinetic function of the pulmonary circulation. Physiol Rev. 1974 Oct;54(4):1007–1045. doi: 10.1152/physrev.1974.54.4.1007. [DOI] [PubMed] [Google Scholar]
  7. Bito L. Z., Baroody R. A., Reitz M. E. Dependence of pulmonary prostaglandin metabolism on carrier-mediated transport processes. Am J Physiol. 1977 Apr;232(4):E383–E387. doi: 10.1152/ajpendo.1977.232.4.E382. [DOI] [PubMed] [Google Scholar]
  8. Caldwell P. R., Seegal B. C., Hsu K. C., Das M., Soffer R. L. Angiotensin-converting enzyme: vascular endothelial localization. Science. 1976 Mar 12;191(4231):1050–1051. doi: 10.1126/science.175444. [DOI] [PubMed] [Google Scholar]
  9. Chandler D. B., Giri S. N. Changes in plasma concentrations of prostaglandins and plasma angiotensin-converting enzyme during bleomycin-induced lung fibrosis in hamsters. Am Rev Respir Dis. 1983 Jul;128(1):71–76. doi: 10.1164/arrd.1983.128.1.71. [DOI] [PubMed] [Google Scholar]
  10. Chandler D. B., Jackson R. M., Briggs A. D., Fuller W. C., Fulmer J. D. The effect of bleomycin on lung metabolism of prostaglandin E2 in hamster. Prostaglandins Leukot Med. 1985 Aug;19(2):139–151. doi: 10.1016/0262-1746(85)90080-0. [DOI] [PubMed] [Google Scholar]
  11. Ghodsi F., Will J. A. Changes in pulmonary structure and function induced by monocrotaline intoxication. Am J Physiol. 1981 Feb;240(2):H149–H155. doi: 10.1152/ajpheart.1981.240.2.H149. [DOI] [PubMed] [Google Scholar]
  12. Gryglewski R. J., Korbut R., Ocetkiewicz A. Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature. 1978 Jun 29;273(5665):765–767. doi: 10.1038/273765a0. [DOI] [PubMed] [Google Scholar]
  13. Hayashi Y., Lalich J. J. Renal and pulmonary alterations induced in rats by a single injection of monocrotaline. Proc Soc Exp Biol Med. 1967 Feb;124(2):392–396. doi: 10.3181/00379727-124-31748. [DOI] [PubMed] [Google Scholar]
  14. Hilliker K. S., Bell T. G., Roth R. A. Pneumotoxicity and thrombocytopenia after single injection of monocrotaline. Am J Physiol. 1982 Apr;242(4):H573–H579. doi: 10.1152/ajpheart.1982.242.4.H573. [DOI] [PubMed] [Google Scholar]
  15. Huxtable R., Ciaramitaro D., Eisenstein D. The effect of a pyrrolizidine alkaloid, monocrotaline, and a pyrrole, dehydroretronecine, on the biochemical functions of the pulmonary endothelium. Mol Pharmacol. 1978 Nov;14(6):1189–1203. [PubMed] [Google Scholar]
  16. Ito K., Nakashima T., Murakami K., Murakami T. Altered function of pulmonary endothelium following monocrotaline-induced lung vascular injury in rats. Br J Pharmacol. 1988 Aug;94(4):1175–1183. doi: 10.1111/j.1476-5381.1988.tb11636.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Juan H. Mechanism of action of bradykinin-induced release of prostaglandin E. Naunyn Schmiedebergs Arch Pharmacol. 1977 Oct;300(1):77–85. doi: 10.1007/BF00505082. [DOI] [PubMed] [Google Scholar]
  18. Kay J. M., Keane P. M., Suyama K. L., Gauthier D. Angiotensin converting enzyme activity and evolution of pulmonary vascular disease in rats with monocrotaline pulmonary hypertension. Thorax. 1982 Feb;37(2):88–96. doi: 10.1136/thx.37.2.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Klein L. S., Fisher A. B., Soltoff S., Coburn R. F. Effect of O2 exposure on pulmonary metabolism of prostaglandin E2. Am Rev Respir Dis. 1978 Sep;118(3):622–625. doi: 10.1164/arrd.1978.118.3.622. [DOI] [PubMed] [Google Scholar]
  20. Lazo J. S., Catravas J. D., Gillis C. N. Reduction in rabbit serum and pulmonary angiotensin converting enzyme activity after subacute bleomycin treatment. Biochem Pharmacol. 1981 Sep 15;30(18):2577–2584. doi: 10.1016/0006-2952(81)90585-2. [DOI] [PubMed] [Google Scholar]
  21. Lazo J. S., Lynch T. J., McCallister J. Bleomycin inhibition of angiotensin-converting enzyme activity from serum, lungs, and cultured pulmonary artery endothelial cells. Am Rev Respir Dis. 1986 Jul;134(1):73–78. doi: 10.1164/arrd.1986.134.1.73. [DOI] [PubMed] [Google Scholar]
  22. Meyrick B., Gamble W., Reid L. Development of Crotalaria pulmonary hypertension: hemodynamic and structural study. Am J Physiol. 1980 Nov;239(5):H692–H702. doi: 10.1152/ajpheart.1980.239.5.H692. [DOI] [PubMed] [Google Scholar]
  23. Molteni A., Ward W. F., Ts'ao C. H., Port C. D., Solliday N. H. Monocrotaline-induced pulmonary endothelial dysfunction in rats. Proc Soc Exp Biol Med. 1984 May;176(1):88–94. doi: 10.3181/00379727-176-41847. [DOI] [PubMed] [Google Scholar]
  24. Ody C., Dieterle Y., Wand I., Stalder H., Junod A. F. PGA1 and PGF2 alpha metabolism by pig pulmonary endothelium, smooth muscle, and fibroblasts. J Appl Physiol Respir Environ Exerc Physiol. 1979 Feb;46(2):211–216. doi: 10.1152/jappl.1979.46.2.211. [DOI] [PubMed] [Google Scholar]
  25. Ryan U. S., Ryan J. W., Whitaker C., Chiu A. Localization of angiotensin converting enzyme (kininase II). II. Immunocytochemistry and immunofluorescence. Tissue Cell. 1976;8(1):125–145. doi: 10.1016/0040-8166(76)90025-2. [DOI] [PubMed] [Google Scholar]
  26. Said S. I. Metabolic functions of the pulmonary circulation. Circ Res. 1982 Mar;50(3):325–333. doi: 10.1161/01.res.50.3.325. [DOI] [PubMed] [Google Scholar]
  27. Sirois P., Brousseau Y., Chagnon M., Gentile J., Gladu M., Salari H., Borgeat P. Metabolism of leukotrienes by adult and fetal human lungs. Exp Lung Res. 1985;9(1-2):17–30. doi: 10.3109/01902148509061525. [DOI] [PubMed] [Google Scholar]
  28. Toivonen H., Hartiala J., Bakhle Y. S. Effects of high oxygen tension on the metabolism of vasoactive hormones in isolated perfused rat lungs. Acta Physiol Scand. 1981 Feb;111(2):185–192. doi: 10.1111/j.1748-1716.1981.tb06723.x. [DOI] [PubMed] [Google Scholar]
  29. Vane J. R. The release and fate of vaso-active hormones in the circulation. Br J Pharmacol. 1969 Feb;35(2):209–242. doi: 10.1111/j.1476-5381.1969.tb07982.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES